Upgrade to SI Premium - Free Trial

Polyrizon Ltd (PLRZ)

14.20 -0.19 (1.32%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (12/19/25 *Est.)

Latest Headlines

Form 6-K Polyrizon Ltd. For: Jul 13 July 13, 2026 4:01 PM - SEC Filing Core AI Holdings names Arie Goor as CFO, effective July 1 July 7, 2026 8:20 AM - StreetInsider Form 6-K Polyrizon Ltd. For: Jul 02 July 2, 2026 4:01 PM - SEC Filing Polyrizon completes biocompatibility tests for NASARIX nasal spray July 2, 2026 7:34 AM - StreetInsider Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial July 2, 2026 7:32 AM - StreetInsider Form 6-K Polyrizon Ltd. For: Jun 29 June 29, 2026 4:01 PM - SEC Filing Polyrizon gets IRB approval for NASARIX allergy blocker trial June 29, 2026 8:45 AM - StreetInsider Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial June 29, 2026 8:44 AM - StreetInsider Form 6-K Polyrizon Ltd. For: Jun 17 June 17, 2026 4:01 PM - SEC Filing Polyrizon patent application for nasal drug delivery platform published in U.S. June 17, 2026 8:16 AM - StreetInsider Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform June 17, 2026 8:15 AM - StreetInsider Form 6-K Polyrizon Ltd. For: Jun 15 June 15, 2026 4:00 PM - SEC Filing Polyrizon initiates human study for NASARIX allergy blocker June 15, 2026 8:05 AM - StreetInsider Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway June 15, 2026 8:05 AM - StreetInsider Form 6-K Polyrizon Ltd. For: Jun 10 June 10, 2026 4:00 PM - SEC Filing Polyrizon receives European patent publication for nasal drug delivery tech June 10, 2026 7:47 AM - StreetInsider Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology June 10, 2026 7:47 AM - StreetInsider Form 6-K Polyrizon Ltd. For: Jun 08 June 8, 2026 4:00 PM - SEC Filing Form 6-K Polyrizon Ltd. For: Jun 08 June 8, 2026 4:00 PM - SEC Filing Polyrizon secures three US sites for NASARIX allergy trial June 8, 2026 9:31 AM - StreetInsider Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial June 8, 2026 9:25 AM - StreetInsider Form 6-K Polyrizon Ltd. For: Jun 05 June 5, 2026 4:01 PM - SEC Filing Form 6-K Polyrizon Ltd. For: May 27 May 27, 2026 4:26 PM - SEC Filing Form 6-K Polyrizon Ltd. For: May 13 May 13, 2026 9:27 AM - SEC Filing Polyrizon secures first U.S. clinical site for allergy blocker trial May 13, 2026 9:25 AM - StreetInsider Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial May 13, 2026 9:25 AM - Globe NewsWire Form EFFECT Polyrizon Ltd. May 5, 2026 6:07 AM - SEC Filing Form 6-K Polyrizon Ltd. For: May 04 May 4, 2026 8:54 AM - SEC Filing Polyrizon submits amended claims for US intranasal drug delivery patent May 4, 2026 8:45 AM - StreetInsider Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform May 4, 2026 8:45 AM - Globe NewsWire Form F-1/A Polyrizon Ltd. April 30, 2026 4:59 PM - SEC Filing Form SCHEDULE 13G Polyrizon Ltd. Filed by: MMCAP International Inc. SPC April 28, 2026 11:06 AM - SEC Filing Form 6-K Polyrizon Ltd. For: Apr 27 April 27, 2026 9:29 AM - SEC Filing Polyrizon files European patent application for drug delivery platform April 27, 2026 9:29 AM - StreetInsider Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform April 27, 2026 9:28 AM - Globe NewsWire Full Article List